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One Sentence Summary:  15 
We have constructed a series of antimicrobial agents called Avidocin-CDs that 16 
specifically bind to the highly polymorphic S-layer and kill C. difficile; rare escape mutants 17 
lacked Surface layer protein A (SlpA) and exhibited severe phenotypic defects that fully 18 
compromised virulence without affecting colonization of the hamster gut. 19 
 20 
Abstract: 21 
Avidocin-CDs are a new class of precision bactericidal agents that do not damage resident gut 22 
microbiota and are unlikely to promote the spread of antibiotic resistance. The precision killing 23 
properties result from the fusion of bacteriophage receptor binding proteins (RBPs) to a lethal 24 
contractile scaffold from an R-type bacteriocin. We recently described the prototypic Avidocin-25 
CD, Av-CD291.2, that specifically kills C. difficile ribotype 027 strains and prevents 26 
colonization of mice. We have since selected two rare Av-CD291.2 resistant mutants of strain 27 
R20291 (RT027; S-layer cassette type-4, SCLT-4). These mutants have distinct point mutations 28 
 2 
in the slpA gene that result in an S-layer null phenotype. Reversion of the mutations to wild-type 1 
restored normal SLCT-4 S-layer formation and Av-CD291.2 sensitivity; however, 2 
complementation with other SCLT alleles did not restore Av-CD291.2 sensitivity despite 3 
restoring S-layer formation. Using newly identified phage RBPs, we constructed a panel of new 4 
Avidocin-CDs that kill C. difficile isolates in an SLCT-dependent manner, confirming the S-5 
layer as the receptor in every case. In addition to bacteriophage adsorption, characterization of 6 
the S-layer null mutant also uncovered important roles for SlpA in sporulation, resistance to 7 
lysozyme and LL-37, and toxin production. Surprisingly, the S-layer-null mutant was found to 8 
persist in the hamster gut despite its completely attenuated virulence. Avidocin-CDs have 9 
significant therapeutic potential for the treatment and prevention of C. difficile Infection (CDI) 10 
given their exquisite specificity for the pathogen. Furthermore, the emergence of resistance 11 
forces mutants to trade virulence for continued viability and, therefore, greatly reduce their 12 
potential clinical impact. 13 
 14 
  15 
 3 
Now 8,020 including supplemental references and study design 1 
Introduction 2 
New antibacterial agents are needed to counteract the impending loss of effective treatment 3 
options for multi-drug resistant bacteria. Furthering this need is the realization that dysbiosis 4 
caused by broad-spectrum antibiotic use contributes to the prevalence of diseases/disorders such 5 
as inflammatory bowel disease, obesity and nosocomial gut infections (1). Strategies to 6 
overcome these threats include the use of narrow spectrum or precision agents and the design of 7 
drugs that target virulence instead of in vitro viability (2, 3). One pathogen for which alternative 8 
treatment approaches are needed is C. difficile. This spore-forming, obligate anaerobe is the 9 
leading cause of nosocomial infections worldwide. Approximately 450,000 cases and 29,000 10 
deaths each year are attributed to this pathogen in the US alone (4). As a result, the Centres for 11 
Disease Control and Prevention has identified C. difficile an urgent threat to human health (5). 12 
This opportunistic pathogen exploits the dysbiosis in the gut that often follows broad spectrum 13 
antibiotic use to proliferate, release toxins, and cause life-threatening colitis (6). Although the 14 
toxins have been studied in great detail, other aspects of C. difficile virulence, including 15 
colonization of the gut, are not well understood (6). The C. difficile cell surface is covered by a 16 
paracrystalline surface layer (S-layer) largely comprised of SlpA and sparsely interspersed by 28 17 
related cell wall proteins (7). The S-layer precursor SlpA is proteolytically processed on the cell 18 
surface to generate the Low and High Molecular Weight S-layer Proteins (LMW and HMW 19 
SLPs). The SLPs interact with high-affinity to form a heterodimer, the basic unit of the mature S-20 
layer (8). The slpA gene is located within a highly variable S-layer cassette consisting of 5 genes 21 
in the C. difficile genome; 13 distinct S-layer cassette types (SLCTs) have been described to date 22 
(9). The variation that defines individual cassette types is largely confined to the LMW SLP-23 
 4 
encoding region of slpA (4). The HMW SLP region is highly conserved and includes the cell 1 
wall binding motifs that anchor the S-layer to the cell wall (10). The S-layer and several 2 
associated cell wall proteins have been implicated in colonization of host tissues (7) and in 3 
stimulation of the host immune response via TLR4 signaling (11).  4 
Whereas C. difficile is not significantly resistant to the frontline antibiotics used to treat CDIs 5 
(vancomycin, metronidazole and fidaxomicin), the use of these antibiotics causes further 6 
disruption of the resident microbiota leading to frequent CDI relapse (6). To be safe and effective 7 
new agents to treat and prevent CDIs must not harm the diverse gut microbiota and the 8 
colonization resistance it provides. Avidocin-CDs represent one such potential agent. (12). These 9 
bactericidal proteins are genetically modified versions of natural R-type bacteriocins produced 10 
by C. difficile (a.k.a. diffocins) to kill competing strains of C. difficile (13). Diffocins and the 11 
derived Avidocin-CDs resemble myoviridae phage tails and consist of a contractile sheath, 12 
nanotube core, baseplate and tail fiber structures. However, instead of delivering DNA across the 13 
bacterial membrane as does a bacteriophage, R-type bacteriocins function as killing machines by 14 
injecting a nanotube core through the bacterial cell envelope and creating a small pore that 15 
dissipates WKHFHOO¶VPHPEUDQHSRWHQWLDO(14). Killing specificity is determined by the receptor 16 
binding proteins (RBPs) located at the tips of the tail fibers that trigger sheath contraction upon 17 
contact with a cognate receptor on the bacterial cell surface. Genetic replacement or fusion of the 18 
RBP gene with homologues from other strains or RBP sources (i.e. C. difficile bacteriophages 19 
and prophage insertions) make it possible to retarget killing (12, 15-17). These modified 20 
bacteriocins are known as Avidocin-CDs. An Avidocin-CD prototype, Av-CD291.2, constructed 21 
with a bacteriophage RBP identified in a prophage insertion was found to be more stable than the 22 
natural parent diffocin, had a modified killing spectrum that included all hypervirulent RT027 C. 23 
 5 
difficile strains tested, blocked C. difficile colonization in a mouse model of spore transmission 1 
and did not disrupt the resident gut microbiota (12). These properties encourage the further 2 
development of Avidocin-CDs as oral human therapeutics.  3 
Here we further characterize the Av-CD291.2 mechanism of action and describe an expanded 4 
panel of Avidocin-CDs that cover all clinically relevant C. difficile strain types using newly 5 
identified bacteriophage RBPs. Rare resistant mutants were isolated in vitro under selection with 6 
Av-CD291.2. Analysis of these mutants aided in the identification of SlpA as the cell surface 7 
receptor for all tested Avidocin-CDs and, by extension, the corresponding RBP-sources, 8 
bacteriophages and prophages. We also identified previously unsuspected roles for SlpA in 9 
sporulation, resistance to lysozyme and the natural anti-microbial peptide LL-37, toxin 10 
production and virulence. Surprisingly, despite their complete attenuation of virulence, resistant 11 
mutants could colonize and persist in the hamster gut for the duration of a 14-day study. These 12 
findings imply that antimicrobial agents that force pathogens to trade virulence for continued 13 
viability would have clear clinical advantages should resistance emerge during treatment.  14 
 6 
Results  1 
Av-CD291.2-resistant mutants lack an S-layer 2 
Resistance to any antimicrobial agent can occur and be exploited to understand its mode 3 
of action. We isolated two spontaneous mutants of C. difficile strain R20291 (ribotype 027) that 4 
were resistant to killing by Av-CD291.2. These mutants appeared at a frequency of < 1 x 10-9 5 
and were found to encode independent point mutations in the slpA gene (Fig. 1A). Both 6 
mutations were predicted to truncate SlpA at a site N-terminal to the post-translational cleavage 7 
site and, thereby, prevent formation of an S-layer. Both FM2.5 and FM2.6 lacked detectable cell 8 
surface S-layer protein subunits as predicted but still expressed minor cell wall proteins such as 9 
Cwp2 and Cwp6 (Fig. 1B). These mutations do not affect the growth rate of the bacteria in vitro 10 
(Fig. S4B); however, FM2.5 displayed a slight, but statistically significant earlier entry into 11 
stationary phase (maximum OD600nm: FM2.5 = 2.2; R20291 = 3.2, p = 0.000012). We attempted 12 
to complement the FM2.5 and FM2.6 mutations with a plasmid-borne wild-type R20291 slpA 13 
allele to confirm resistance to Av-CD291.2 was due to loss of the S-layer; however, unexpected 14 
homologous recombination restored the wild type slpA gene to the chromosome (Fig. S1). 15 
Accordingly, we created genetically LGHQWLILDEOHUHFRPELQDQWV³ZDWHUPDUNHG´ZLWKV\QRQ\PRXV16 
substitutions in the R20291 slpA allele (Fig. 1A). The resulting strains, FM2.5RW and 17 
FM2.6RW, were found to have LMW and HMW SLPs on their surface (Fig. 1B) and regained 18 
sensitivity to Av-CD291.2 (Fig. 1C and D). These results confirmed that an intact S-layer is 19 
required for Av-CD291.2 killing but did not determine whether SlpA itself or a protein 20 
dependent on the S-layer for surface localization was the receptor for Av-CD291.2. To begin to 21 
address this question, slpA alleles from the most common non-R20291 SLCTs were individually 22 
cloned into an inducible expression plasmid and transferred into the S-layer deficient FM2.5 23 
 7 
(Fig. 1E). Each resulting strain expressed the expected LMW and HMW SLPs on the cell 1 
surface, indicative of S-layer formation (9), but did not regain sensitivity to Av-CD291.2, thus, 2 
ruling out the possibility that the simple formation of an S-layer was responsible for sensitivity to 3 
Av-CD291.2. To address whether Av-CD291.2 directly interacts with SLCT-4 SlpA, plasmids 4 
encoding SlpAs from 8 different SLCTs were introduced into the non-isogenic laboratory strain 5 
630 (SLCT-7; ribotype 012), which is insensitive to Av-CD291.2 (Table S1). In this fully S-layer 6 
competent SLCT-7 wild type strain, only induction of SLCT-4 SlpA was sufficient to confer 7 
sensitivity to Av-CD291.2 (Fig. S3). Moreover, the degree of sensitivity was dependent on the 8 
level of induction with only 10 ng/mL of inducer required (Fig. S3A). Taken together these 9 
observations clearly demonstrate that the SLCT-4 variant of SlpA is the cell surface target of Av-10 
CD291.2. 11 
Sensitivity to all Avidocin-CDs is slpA allele-specific 12 
This series of observations suggested that each variant of SlpA may serve as a specific 13 
receptor for additional C. difficile bacteriophage RBPs. In an attempt to expand Avidocin-CD 14 
coverage beyond SLCT-4, we constructed ten new Avidocin-CDs using predicted bacteriophage 15 
RBPs mined from the genome sequences of C. difficile clinical isolates or of newly isolated 16 
bacteriophages (Table S1). Source strains for RBP sequences were chosen based on their SLCT 17 
since strain typing information for the RBP source often correlates with sensitivity to the 18 
corresponding Avidocin (e.g. ribotype 027 and sensitivity to Av-CD291.2; SLCT-1 of phi-147 19 
propagating strain and sensitivity to Av-CD147.1) (12, 15, 16). Preparations of Diffocin-4 20 
(scaffold for all Avidocin-CDs), Av-CD291.2, and each of the new Avidocin-CDs were tested 21 
for killing activity on a panel of 62 C. difficile isolates containing all 13 known SLCTs and a 22 
newly identified 14th SLCT (Fig. S2). Only two strains, representing SLCTs 3 and 5, were not 23 
 8 
killed by a single Avidocin-CD (Fig S2); otherwise, every isolate from all 12 other SLCTs was 1 
killed by at least one Avidocin-&'$QHDUSHUIHFWFRUUHODWLRQZDVREVHUYHGEHWZHHQDVWUDLQ¶s 2 
SLCT and its sensitivity to each of the Avidocin-CDs. The only exceptions were SLCT-2 3 
isolates with Av-CD027.2 and Av-CD685.1. A strong correlation was also observed between 4 
ribotype and sensitivity to a particular Avidocin-CD since all ribotypes in the panel, except 012, 5 
014 and 015, were found to associate exclusively with a single SLCT. Similar correlations with 6 
strain sensitivity and SLCT or ribotype were not observed for killing with Diffocin-4, suggesting 7 
this natural R-type bacteriocin binds to C. difficile via another receptor. 8 
Having made these observations, we wanted to determine if sensitivity to specific 9 
Avidocin-CDs was directly dependent upon the variant of SlpA present. The panel of isogenic 10 
FM2.5 strains complemented with slpA alleles from the 10 most common SLCTs was tested for 11 
sensitivity to a panel of the most potent Avidocin-CDs (Fig. 2). The corresponding parental 12 
strains from which the slpA alleles were obtained were used as controls. Each complemented 13 
strain became sensitive to the same Avidocin-CDs as the parental strain. To confirm that this 14 
induced sensitivity did not result from altered cell surface architecture in the slpA mutant, an 15 
analogous experiment was performed in a second isogenic panel of strains that was created when 16 
plasmids encoding SlpAs from 8 SLCTs were introduced into the S-layer competent strain 630. 17 
As before, the spectrum of killing was identical to that of the parental strains from which the 18 
slpA alleles were obtained. These data conclusively demonstrate that the polymorphic SlpA acts 19 
as the binding receptor for each of the Avidocin-CDs tested and, therefore, the corresponding 20 
bacteriophage RBPs. 21 
S-layer null mutants are abnormally sensitive to innate immune effectors 22 
 9 
Bacterial S-layers serve many critical cellular functions (7). Analysis of these functions 1 
in C. difficile have been greatly hampered by the fact that slpA-deficient mutants had proved 2 
recalcitrant to isolation prior to the isolation of FM2.5 and FM2.6 (18). Given its location on the 3 
cell surface, the S-layer has been proposed to act as a molecular sieve to selectively limit 4 
exposure of the underlying cell envelope to large biomolecules such as the innate immune 5 
effector lysozyme (19). While C. difficile is highly resistant to killing by this enzyme, resistance 6 
has been attributed to extensive peptidoglycan deacetylation (20). To determine if the S-layer 7 
also plays a role in lysozyme resistance, we treated exponentially growing bacteria with a high 8 
concentration of lysozyme (500 ȝJPO) and monitored the effects on growth (Fig. 3A). Upon 9 
addition of lysozyme an immediate decrease in optical density consistent with cell lysis, 10 
followed by slower growth, was observed for the S-layer mutant FM2.5. In contrast, R20291 and 11 
FM2.5RW displayed only a transient decrease in growth rate, consistent with natural resistance. 12 
Having confirmed a role for the S-layer in lysozyme resistance, we then tested for resistance to 13 
the human cathelicidin antimicrobial peptide LL-37 to determine if S-layer-mediated resistance 14 
extended to other innate immune effectors (Fig. 3B). LL-37 is found at mucosal surfaces at 15 
concentrations of up to 5 ȝg/ml in normal conditions with further expression induced in response 16 
to infection (21). Treatment with 5 ȝg/ml of LL-37 completely killed an exponentially growing 17 
culture of the S-layer mutant FM2.5; whereas, the same treatment caused only a slight reduction 18 
in growth rates of R20291 and FM2.5RW. Taken together, these data demonstrate a role for the 19 
S-layer in resistance to both lysozyme and LL-37.  20 
S-layer null mutants display severe sporulation defects 21 
It was noted that the S-layer mutant strains survived poorly in the standard charcoal 22 
medium used to transport C. difficile strains. The ability of C. difficile to survive in the 23 
 10 
environment and be transmitted to new hosts is reliant on the EDFWHULXP¶Vability to produce heat 1 
and chemical-resistant spores (22). We analyzed sporulation efficiency by measuring the 2 
numbers of heat-resistant spores as a percentage of total viable CFUs over 5 days (Fig. S4A). 3 
Spore production by wild type R20291 and FM2.5RW cultures was reproducible and equivalent 4 
and represented 73 and 85% of total viable counts on day 5, respectively (Fig. 3C). In contrast, 5 
spore production by FM2.5 was significantly lower (p = <0.00001). Spores only represented 6 
4.3% of total viable counts on day 5, which is a 17-20-fold reduction compared to R20291 and 7 
FM2.5RW. These observed differences in FM2.5 spore formation were not due to an inability to 8 
germinate efficiently (Fig. 3D). When the bile salt germinant taurocholate was added to purified 9 
spore preparations, the speed and efficiency of germination initiation for FM2.5 spores was 10 
indistinguishable from that of R20291 and FM2.5RW. Analysis of bacterial cultures by phase 11 
contrast microscopy also pointed to a reduction in sporulation efficiency (Fig. S4C and D), as 12 
5.2-fold fewer phase bright spores were observed in cultures of FM2.5 (FM2.5, 8.7% vs R20291, 13 
44.9%; FM2.5RW, 45.4%). Interestingly, we noted a discrepancy between the magnitudes of the 14 
sporulation defect determined microscopically (5.2-fold less than R20291) compared with direct 15 
counting of viable spore CFUs (20-fold less than R20291). This suggests that many of the 16 
microscopically counted spores were nonviable following the 65°C heat treatment required to 17 
differentiate spores from vegetative cell CFUs. To test the FM2.5 spores for possible stress 18 
resistance defects, we exposed the cultures to a harsher heat treatment (75°C for 30 min). The 19 
75°C heat treatment further reduced FM2.5 spore viability 33-fold compared with the standard 20 
65°C (Fig. 3C). The same treatment only reduced spore viability by 1.5-fold for R20291 and 2-21 
fold for FM2.5RW. Collectively, these data indicate that the production and quality of the 22 
infectious spores are severely impaired by the loss of the S-layer.  23 
 11 
Transmission electron microscopy was employed to identify potential morphological 1 
changes associated with these defects (Fig. S5). In FM2.5 cultures we observed spores with 2 
disorganized material loosely attached to the electron-dense core that lacked discernible, well-3 
organized protein coat layers (23)(Fig. S5A). To determine if these unusual spore morphologies 4 
were responsible for the observed thermal sensitivity, we repeated these analyses with spores 5 
purified on a Histodenz gradient. Following purification, spores of FM2.5 were morphologically 6 
indistinguishable from those of R20291 and FM2.5RW (Fig. S5C). Surprisingly however, 7 
purified FM2.5 spores still displayed increased thermal sensitivity, with a 75°C heat treatment 8 
reducing FM2.5 spore viability 37.1-fold compared with 10- and 18.1-fold for R20291 and 9 
FM2.5RW respectively (Fig. S5B). Several distinct biochemical and structural features of the 10 
spore, including the concentric cortex peptidoglycan and protein layers and core dehydration, 11 
have been independently linked to heat resistance (24-26). Minor defects in any of these features 12 
could explain the observed thermal sensitivity of FM2.5 spores. 13 
S-layer null mutants are completely avirulent despite persistent gut colonization 14 
We tested the ability of the S-layer mutant FM2.5 to cause disease in the Golden Syrian 15 
hamster model of acute CDI. As expected, all animals inoculated with FM2.5RW behaved 16 
similarly to animals inoculated with the wild type R20291 strain and succumbed to C. difficile 17 
infection within 102 h of infection, with mean times to cull for R20291 and FM2.5RW of 67 h 18 
36 min and 57 h 19 min, respectively (p = 0.52, Fig. 4A). Both groups of hamsters showed 19 
typical signs of disease including wet tail and drop in body temperature at experimental 20 
endpoint. In contrast, all animals inoculated with FM2.5 displayed no signs of disease and 21 
survived for the duration of the 14-day study (p = 0.0018; FM2.5 vs R20291, Fig. 4A). Very few 22 
described mutations located outside of the PaLoc locus have resulted in complete avirulence in 23 
 12 
this model (27). Surprisingly, the lack of virulence was not due to a colonization defect. FM2.5 1 
was capable of persistent colonization; CFUs in the caecum and colon at the end of study (14 2 
days) were not statistically different to those observed for R20291 and FM2.5RW in the same 3 
tissues taken at experimental endpoint some 10 days earlier (Fig. 4B). Toxin measurements from 4 
gut contents 14 days after inoculation with FM2.5 showed dramatic reductions in both toxin A or 5 
B activity compared to samples taken from hamsters that succumbed to infection with either the 6 
R20291or FM2.5RW (Fig. 4C and 4D). 7 
S-layer null mutants lack toxin production in vitro 8 
Given the avirulence and low toxin activity observed in animals, we assayed the FM2.5 9 
and control strains for toxin production in vitro (Fig. 4E). Toxin B was used as an indicator for 10 
both toxins since they are coordinately expressed and released (6). As expected, both R20291 11 
and FM2.5RW produced toxin upon entry into stationary phase. A small amount of Toxin B was 12 
detected intracellularly at 24 hours; thereafter, Toxin B was exclusively detected in the culture 13 
supernatant. Cultures of FM2.5 produced less Toxin B at all time-points, consistent with in vivo 14 
observations. 15 
 16 
  17 
 13 
Discussion  1 
The bactericidal properties of Avidocin-CDs bode well for the clinical application of this 2 
new class of antimicrobial agents for combating CDI. Previous studies demonstrated that killing 3 
by the prototypic Avidocin-CD, Av-CD291.2, was highly specific for BI/NAP1/027-type strains 4 
and did not detectably alter the resident gut microbiota in mice (12). For production purposes 5 
fermentation of genetically modified B. subtilis expressing these agents is similar to many 6 
established industrial processes and scalable to thousands of liters. We selected, isolated and 7 
characterized rare C. difficile mutants resistant to Av-CD291.2 to better understand its 8 
mechanism of action. In the process we discovered the Avidocin-CD binding receptor, the C. 9 
difficile S-layer protein SlpA. Indeed, our 10 new Avidocin-CDs were all found to target variants 10 
of SlpA associated with different SLCTs. Given that the great majority of the sequence variation 11 
in SlpA is found within the surface exposed LMW subunit (9), this relationship between SLCT 12 
and Avidocin-CD sensitivity strongly suggests that the LMW SLP is the binding site for all the 13 
studied Avidocin-CDs. Further, it indirectly identifies this portion of the SlpA as the binding 14 
receptor for many C. difficile myophages since each Avidocin-CDs is constructed with a 15 
different bacteriophage-derived RBP. These findings help explain the limited host ranges 16 
observed for many C. difficile myophages (28, 29). It also suggests that antigenic variation 17 
observed between SLCTs may not be due to immune escape as previously proposed (9) but 18 
rather due to a molecular arms race between bacteria and bacteriophages. C. difficile is under 19 
selective pressure to change the bacteriophage receptor, which in turn puts selective pressure on 20 
the bacteriophages to evolve new RBPs.  21 
 Interestingly, patterns of strain sensitivity to each Avidocin-CD indicate killing was 22 
much broader than the parental EDFWHULRSKDJH¶VKRVWrange (Fig. S2 and S7). A possible 23 
 14 
explanation for this observation is that a typical bacteriophage infection cycle is a 7-step process: 1 
attachment, genome injection, replication, transcription, translation, assembly and lysis. Bacteria 2 
can become resistant to a bacteriophage by blocking any stage of the infection cycle. For 3 
example, CRISPR-Cas or restriction-modification systems that prevent phage DNA from 4 
replicating (30). In contrast, Avidocin-CD killing is a 2-step process: attachment to the target 5 
bacterium followed by killing via creation of a small pore that dissipates WKHWDUJHWEDFWHULXP¶V6 
membrane potential, importantly, without lysis or release of macromolecules such as exotoxin 7 
from the cytoplasm (Fig. S6). As observed with other Avidocins and R-type bacteriocins (16, 8 
31), selected Avidocin-CD resistant mutants survived due to mutations that caused the loss or 9 
modification of the SlpA binding receptor and not due to mutations that directly disrupted the 10 
killing mechanism, such as improper pore formation, or caused proteolytic cleavage of the agent. 11 
The bias towards receptor mutations suggests the Avidocin-CD killing mechanism is simple and 12 
robust.  13 
Modification of the binding receptor to avoid Avidocin-CD killing either through 14 
missense mutations or S-layer switching, as evidenced by the random association between clades 15 
and SLCTs (9), could also theoretically lead to resistance. While sequence variations between 16 
slpA alleles within each SLCT indicate missense mutations do occur (9), our findings suggest 17 
resistance due to this type of modification is unlikely since the bacteriophage RBPs used to 18 
construct the Avidocin-CDs have already evolved to counter this mode of potential escape. For 19 
instance, both Av-CD684.1 and Av-CD685.1 kill every SLCT-7 strain tested despite sequence 20 
identities between SLCT-7 SlpAs as low as 81% (Fig. S8). As for the emergence of resistance 21 
via horizontal transfer of the S-layer cassette, the administration of a cocktail of Avidocin-CDs 22 
that kill all the common SLCTs would make successful resistance via S-layer switching 23 
 15 
extremely unlikely. It appears that the only likely means of resistance to all the Avidocin-CDs is 1 
through complete loss of SlpA, as observed for resistance to Av-CD291.2. As a consequence the 2 
observed phenotypes for FM2.5 are germane to all likely Avidocin-CD-resistant mutants. 3 
For a precision medicine agent to be successful, knowing the molecular target, in this 4 
case the binding receptor, is vital in designing accurate diagnostics to guide treatment decisions. 5 
If Avidocin-CDs were to be administered individually, a diagnostic determining SLCT of 6 
infecting C. difficile would be highly accurate for informing Avidocin-CD treatment decisions. 7 
However, an increase in the prevalence of hybrid cassettes, as found in ribotype 078 strains (9), 8 
would decrease the accuracy for this typing method. Strain ribotyping could also be employed to 9 
avoid development of new diagnostics, but predicting sensitivity to a particular Avidocin-CD 10 
may be challenging as ribotypes are not consistently linked to a single SLCT (i.e. 012, 014, and 11 
015, as noted above). SlpA-typing would provide the most accurate diagnostic as well as prove 12 
more illuminating than ribotyping since SlpA is directly related to the physiology of C. difficile, 13 
whereas, ribotyping detects physiologically inconsequential ribosomal RNA gene 14 
polymorphisms. It may also be possible to administer a cocktail of 5-6 Avidocin-CDs that target 15 
12 of the 14 C. difficile SLCTs. If such a cocktail of Avidocin-CDs were to be administered, a 16 
point of care diagnostic would only need to detect the presence of C. difficile to guide treatment 17 
decisions. 18 
The strong selective pressure afforded by Av-CD291.2 allowed isolation of the first 19 
spontaneous C. difficile S-layer null mutants. In addition to enabling identification of the 20 
Avidocin-CD cell surface receptor, these mutants also provide an unprecedented opportunity to 21 
study S-layer function (Fig. 5). Given the ubiquity of S-layers in both Bacteria and Archaea, 22 
including many pathogenic species, surprisingly little is known about their function. It has been 23 
 16 
suggested that the S-layer could act as a molecular sieve to exclude certain large biomolecules 1 
from the cell envelope (19); however, this has not been confirmed in live cells. We have 2 
demonstrated that an intact S-layer is required for resistance to two components of the innate 3 
immunity system, lysozyme and the antimicrobial peptide LL-37. Assembled S-layers are highly 4 
symmetrical with regular repeating pores. The size of the pores in the C. difficile S-layer is not 5 
yet known but in other species pore sizes of between 2 and 6 nm have been reported. A pore size 6 
of 2 nm could conceivably exclude the16 kDa globular protein lysozyme but a small peptide 7 
such as LL-37 would experience no such steric hindrance. It is possible that charged surfaces on 8 
the assembled S-layer serve to sequester the cationic peptide away from the cell envelope in a 9 
manner analogous to capsular polysaccharides (32). Our data has identified other pleiotropic 10 
functions for the C. difficile S-layer. It is clear that the S-layer is the cell surface receptor for all 11 
of the Avidocin-CDs described here and, by extension, the receptor for the bacteriophages from 12 
which the RBP-encoding genes were cloned. Although a Bacillus bacteriophage has been found 13 
to bind S-layer protein Sap (33), this is the first time a receptor for a C. difficile bacteriophage 14 
has been identified. Furthermore, our data imply that S-layer recognition is a common feature of 15 
bacteriophages that infect this species. 16 
Surprisingly, the S-layer mutant also displayed severe sporulation defects, with fewer and 17 
morphologically defective spores produced. Despite a number of well-studied spore-forming 18 
organisms producing S-layers, including B. anthracis (33), S-layer biogenesis has not been 19 
reported previously to affect sporulation. There is currently no evidence to suggest that the SLPs 20 
are a structural part of the mature spore and the mechanisms by which the S-layer can influence 21 
sporulation are currently unknown. However, this observation has serious ramifications for the 22 
ability of an Avidocin-CD-resistant, S-layer defective mutant to survive and be transmitted to 23 
 17 
other hosts. The spore is an absolute requirement for C. difficile survival in the aerobic 1 
environment and is critical for transmission (22). In addition to sporulation defects, the S-layer 2 
mutant was also found to produce less toxin in vitro. Interestingly, there have been previous 3 
suggestions of feedback between sporulation and the complex regulatory network controlling 4 
toxin production (22). Although the mechanism by which these processes are affected in SlpA 5 
null mutants is far from clear, it is possible that the S-layer feeds into a point of crosstalk 6 
between regulation of virulence and transmission. Given the poor toxin production and other 7 
diverse phenotypes identified for the S-layer mutant, it is probably not surprising that the mutant 8 
was entirely avirulent in the hamster model of acute infection. What did come as a surprise, 9 
however, was the ability of the S-layer mutant to stably colonize and persist in the hamster gut 10 
for the 14-day duration of the experiment. Previous reports have pointed to a role for the S-layer 11 
in epithelial cell adhesion; however, these earlier studies were performed without access to an 12 
slpA-defective strain (34). The S-layer defective mutants and isogenic controls expressing the 13 
SLCT-specific slpA alleles provide the ideal controls to test these conflicting findings and better 14 
define the effect SlpA type has on these functions. 15 
There are several study limitations that should be considered when evaluating the data 16 
presented. The activity of each new Avidocin-CD was observed in vitro and needs to be 17 
confirmed in an animal treatment model, as done for Av-CD291.2. Similarly, the exquisite 18 
specificity of each agent for distinct C. difficile SLCTs also needs be tested in vivo to confirm 19 
that treatment with these agents will not alter the diversity of the gut microbiota. The avirulent 20 
phenotype and long-term persistence of the Avidocin-CD-resistant slpA mutants in the hamster 21 
model should also be confirmed in other animal species. Finally, the implications of WKHPXWDQWV¶22 
 18 
observed sporulation defects on transmission and the spread of resistance remain to be tested in 1 
vivo. In all cases, we do not anticipate different outcomes from those described here. 2 
After accounting for these limitations, analysis of the data clearly demonstrates that 3 
acquisition of Avidocin-CD resistance results in loss of toxin production and complete loss of 4 
virulence. Virulence factors make attractive targets for new antimicrobials as they tend to be 5 
species-specific, and emergence of resistance is likely to reduce virulence. The ability of the S-6 
layer mutant to stably colonize the gut in the absence of clinical disease reveals that the in vivo 7 
lifestyle of the organism is independent of virulence. The prevalence of non-toxigenic, avirulent 8 
C. difficile strains in the general population (35) supports this hypothesis. As a result, we predict 9 
that there will be no competing selective pressure to restore virulence in the context of Avidocin-10 
CD resistance. 11 
 In summary, we have developed and characterized multiple new Avidocin-CDs, 12 
providing crucial insights into their potential advantages in the clinic. The precise killing activity 13 
of Avidocin-CDs makes them attractive agents for both treatment and prevention since they can 14 
be administered to patients without altering the diversity of the complex gut microbiota. In 15 
addition, when resistance does emerge, Avidocin-CDs force the pathogen to sacrifice virulence 16 
for viability - making the potential clinical impact of resistance inconsequential.  17 
 19 
Materials and Methods 1 
Study design 2 
The objective of this study was to characterize a panel of Avidocin-CDs, anti-bacterial protein 3 
complexes constructed to specifically target and kill C. difficile. During these experiments, the 4 
isolation of Avidocin-CD resistant slpA mutants allowed detailed analysis of S-layer function for 5 
the first time. Starting from the prototypic Av-CD291.2 (12) we constructed a panel of new 6 
Avidocin-CDs using bacteriophage RBPs we identified. Each new Avidocin-CD displayed a 7 
unique spectrum of killing activity with a strong correlation to SLCT. Sensitization of two 8 
insensitive C. difficile strains by heterologous expression of a cognate SLCT SlpA alone allowed 9 
identification of the S-layer as the receptor for all described Avidocin-CDs. Analysis of the slpA 10 
mutant identified previously unsuspected in vitro roles for the S-layer in resistance to the 11 
immune effectors lysozyme and LL-37, and in the production of mature heat-resistant spores. 12 
Finally, use of the Golden Syrian hamster model of acute infection demonstrated that the slpA 13 
mutant was entirely avirulent despite persistent infection. Despite colonization, greatly reduced 14 
toxin activity was detected in intestinal contents from animals infected with the slpA mutant and 15 
this observation was supported by identification of a toxin production defect in vitro. The design 16 
and execution of these animal experiments is described in detail in Supplementary Methods. 17 
 18 
Strains, bacteriophage and culture conditions. 19 
Bacterial strains used in this study are described in Figure S2. DNA oligonucleotides are 20 
described in Table S2. E. coli strains were routinely grown in LB broth and on LB agar (VWR). 21 
C. difficile strains were routinely grown under anaerobic conditions on BHI or BHI-S agar and in 22 
TY broth (36) except where otherwise stated. Cultures were supplemented with chloramphenicol 23 
 20 
(15 ȝg/ml), thiamphenicol (15 ȝg/ml) or anhydrotetracycline (20 ng/ml) as required. C. difficile 1 
SLCTs were determined by analyzing the nucleotide sequence of the slpA gene. When necessary, 2 
the slpA gene was sequenced using oligonucleotide primers previously described (37, 38) or 3 
primers 023-F and 023_010-R or 014+++-F and 014_002+-R (nucleotide sequences - Table S2). 4 
The variable region of strain 19142 (ribotype 046) slpA gene did not display high sequence 5 
identity with other slpA alleles, and has been designated SLCT-13. A partial strain 19142 slpA 6 
sequence was deposited in Genbank (accession: KX610658). Details of plasmid and strain 7 
construction are given in Supplementary Methods. 8 
 9 
Isolation of Av-CD291.2-resistant clones. 10 
A greater than 100-fold excess of active Av-CD291.2 was added to exponentially growing C. 11 
difficile strain R20291. After 75 min bacteria were harvested, resuspended in phosphate buffered 12 
saline (PBS), and spread on non-selective Brucella agar plates maintained under anaerobic 13 
conditions at 37°C overnight. CFU counts before and after Av-CD291.2 addition were compared 14 
to determine resistance frequency. Resistant colonies were streaked on C. difficile-selective agar 15 
and Av-CD291.2-resistance was confirmed. Av-CD291.2-resistant strains FM2.5 and FM2.6 was 16 
sequenced by Illumina Miseq and identified slpA mutations were confirmed by Sanger 17 
sequencing. 18 
 19 
Bioassays to determine Avidocin-CD killing activity. 20 
Avidocin-CD bactericidal activity was assayed by a semi-quantitative spot method as previously 21 
described (12, 13). For broth-based killing assays, C. difficile strains were grown overnight in 22 
TY broth and then sub-cultured to an OD600nm of 0.05 in 1 ml fresh TY supplemented with 1mM 23 
 21 
CaCl2. Av-CD291.2 (50 Pl) was added to each culture after 2.5 h. Growth was monitored by 1 
measuring the OD600nm hourly. 2 
 3 
Extraction of S-layer and associated proteins. 4 
S-layer proteins were extracted using low pH glycine as previously described (8) and analyzed 5 
by SDS-PAGE using standard methods. 6 
 7 
Quantitative analysis of sporulation and germination. 8 
Quantitative analysis of sporulation was carried out as previously described (18) and monitored 9 
by phase contrast and transmission electron microscopy as described in Supplementary Methods.  10 
 11 
Analysis of resistance to lysozyme and LL-37. 12 
Broth based killing assays were carried out as described above but with Lysozyme (500 Pg/ml) 13 
or LL-37 (5 Pg/ml) added after 2.5 h growth. Cell density was monitored by measuring the 14 
OD600nm hourly. Assays were carried out in triplicate on biological duplicates.  15 
 16 
Animal experiments. 17 
The Golden Syrian hamster model was performed as previously described (39). All procedures 18 
were performed in strict accordance with the Animals (Scientific Procedures) Act 1986 with 19 
specific approval granted by the Home Office, U.K. (PPL60/4218). Further detail is given in 20 
Supplementary Methods. 21 
 22 
Quantification of toxin expression. 23 
 22 
Quantification of toxin activity was performed using Vero cells as described previously (39) and 1 
by Western immunoblot using anti-Toxin B antibody. Further details are given in Supplementary 2 
methods. 3 
 4 
Statistical analyses. 5 
Data were analyzed using GraphPad Prism software (GraphPad Software Inc.). Toxin production 6 
was compared using a two-tailed nonparametric Mann-Whitney test, and animal survival curves 7 
were analyzed using a Log-rank (Mantel-Cox) test. All other statistical analyses were performed 8 
using two-tailed t-tests with Welch's correction.  9 
10 
 23 
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Figure Legends:  1 
Fig. 1. Mutations in slpA confer Av-CD291.2 resistance. (A) Alignment of the slpA sequence 2 
(nucleotides 268-294) from R20291, FM2.5, FM2.6, FM2.5RW and FM2.6RW. A nucleotide 3 
insertion at position 283 of FM2.5 slpA results in a frameshift and premature stop codon (in 4 
blue). A nucleotide substitution at position 280 of FM2.6 slpA results in a nonsense mutation (in 5 
red). To allow differentiation from the wild type sequence two synonymous mutations were 6 
introduced into slpA in FM2.5RW and FM2.6RW (in green) (B) SDS-PAGE analysis of S-layer 7 
extracts from R20291, FM2.5, FM2.6, FM2.5RW and FM2.6RW. The positions of the LMW 8 
and HMW SLPs and minor cell wall proteins Cwp2 and Cwp6 are indicated. (C and D) The 9 
impact of Av-CD291.2 on exponentially growing R20291, FM2.5, FM2.5RW and FM2.6RW 10 
was monitored by measuring the optical density at 600 nm. Av-D291.2 addition is indicated with 11 
an arrow. Experiments were carried out in triplicate on biological duplicates. Means and standard 12 
deviations are shown. (E) SDS-PAGE analysis and Av-CD291.2 sensitivity of FM2.5 13 
complemented with slpA alleles from multiple SLCTs following induction with 14 
anhydrotetracycline (20 ng/ml). R20291 and FM2.5RW are included as controls. A zone of 15 
clearance in the agar lawn indicates killing. 16 
 17 
Fig. 2. Avidocin-CD sensitivity correlates with SLCT. (A) SDS-PAGE analysis of SLPs 18 
extracted from a panel of strains representing the 11 most commonly isolated SLCTs. (B) Spot 19 
bioassays with 8 Avidocin-CDs on the C. difficile strains used in panel A, as well as FM2.5 alone 20 
(-) and FM2.5 complemented with slpA alleles from 10 SLCTs following induction with 21 
anhydrotetracycline (20 ng/ml). The zone of clearance caused by each Avidocin-CD is shown 22 
along with SLCT (H = Hybrid 2/6). 23 
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 1 
Fig. 3. Phenotypic characterization of FM2.5. (A and B) Cultures of R20291, FM2.5 and 2 
)05:ZHUHFKDOOHQJHGZLWKO\VR]\PHȝJPOA) or LL-ȝJPOB) in exponential 3 
phase after 2.5 h (indicated with arrows). Untreated control cultures were grown in parallel. 4 
Experiments were carried out in triplicate on biological duplicates. Means and standard 5 
deviations are shown. (C) Sporulation of R20291, FM2.5, and FM2.5RW after 5 days. Spore 6 
CFUs were determined following a standard 65°C heat treatment for 30 minutes or a harsher 7 
75°C heat treatment for 30 minutes. Heat-resistant spore CFUs are expressed as a percentage of 8 
total viable CFUs (spores and vegetative cells). Experiments were carried out in duplicate on 9 
biological duplicates. Mean and standard deviation are shown. * = P<0.01, determined using 10 
using two-tailed t-tests with Welch's correction. (D) Germination of R20291, FM2.5, and 11 
FM2.5RW spores. Synchronous germination of purified spores was induced with the bile salt 12 
taurocholate. Germination initiation was monitored by measuring the resulting decrease in 13 
optical density at OD600nm. 14 
 15 
Fig. 4. In vivo analysis of slpA mutant in the Syrian Golden hamster. (A) Times to experimental 16 
endpoint of animals infected with R20291 (black line), FM2.5 (dark blue line) and FM2.5RW 17 
(light blue line) respectively. Each line represents 6 animals. (B) Total CFUs and spore CFUs 18 
(following heat treatment at 56°C for 20 min) were determined for Lumen- (LA) and tissue-19 
associated (TA) bacteria recovered from caecum (CAE) and colon (COL) of infected animals 20 
and quantified at experimental endpoint (R20291 and FM2.5RW) or at 14 days post-infection 21 
(FM2.5). Shown are the mean and standard error. The horizontal dotted line indicates the limit of 22 
detection. None of the observed differences, including those for the TA-spore CFUs from the 23 
 34 
colon, are statistically significant. (C and D) Relative toxin activity of filtered gut samples on 1 
HT-29 (toxin A) and Vero cells (toxin B) respectively. Values represent the reciprocal of the first 2 
dilution in which cell morphology was indistinguishable from untreated wells. Samples were 3 
taken at experimental endpoint (R20291 and FM2.5RW) or at 14 days post-infection (FM2.5). (* 4 
= P <0.05, ** = P <0.01, NS = not significant, determined using using a two-tailed 5 
nonparametric Mann-Whitney test. (E) In vitro cell lysate and culture supernatant samples from 6 
R20291, FM2.5 and FM2.5RW were normalized to an equivalent optical density and separated 7 
on 6% SDS polyacrylamide gels. Toxin B was detected by Western immunoblot using an anti-8 
Toxin B monoclonal antibody. Samples were taken at the indicated time points. 9 
 10 
Fig. 5. Schematic diagram depicting the phenotypes of Wild Type (A) and S-layer null mutant 11 
(B) cells in C. difficile biology and pathophysiology. Processes labeled in black indicate new 12 
functions discerned in this manuscript. Processes labeled in grey indicate previously identified 13 
functions. Dotted lines indicate relationships that need to be studied further. Question marks 14 
indicate previously described connections incompatible with observations made with the S-layer 15 
null mutant and warranting further investigation. (C) Schematic of Avidocin-CD structure and 16 
function. Binding to C. difficile by the Avidocin-CD receptor binding proteins (RBPs) triggers 17 
the sheath to contract and force the hollow nanotube core across the cell envelope. The resulting 18 
pore allows small metabolites, such as protons, ATP and cations, to escape from the cell 19 
cytoplasm, which, in turn, disrupts WKHFHOO¶s membrane potential and kills the cell. 20 
